NCT03720496Unknown1 期
Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells
Timmune Biotech Inc.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2018年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）
研究概览
简要总结
This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19 Positive Non-Hodgkin Lymphoma (NHL).
详细描述
The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the CD19-TriCAR-T to simultaneously targeting the CD19 positive NHL cells，blocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must personally sign and date the consent form before initiating any study specific procedures or activities;
- •All subjects must be able to comply with all the scheduled procedures in the study;
- •Histologically or cytologically confirmed CD19 positive non-Hodgkin lymphoma;
- •At least one measurable lesion per revised IWG Response Criteria;
- •Aged 18 to 69 years;
- •Expected survival ≥12 weeks;
- •Eastern cooperative oncology group (ECOG) performance status of ≤2;
- •Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;
- •All other treatment induced adverse events must have been resolved to
- •Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB >70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);
排除标准
- •Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment;
- •Patients with symptomatic central nervous system metastasis, intracranial metastasis, and cancer cells found in cerebrospinal fluid are not recommended to participate in this study. Symptom free or post-treatment stable disease or disappearance of lesions should not be excluded. The specific selection is ultimately determined by the investigator;
- •Lactating women;
- •Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive);
- •Known history of infection with HIV;
- •Subjects need systematic usage of corticosteroid;
- •Subjects need systematic usage of immunosuppressive drug;
- •Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study;
- •Other reasons the investigator think the patient may not be suitable for the study.
结局指标
主要结局
safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）
时间窗: 24 months
Incidence of treatment-related adverse events as assessed by CTCAE v4.03
次要结局
- Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）(24 months)
- Duration of Response （The time from response to relapse or progression）(24 months)
- Overall Survival （The number of patient alive, with or without signs of cancer）(24 months)
- Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)(24 months)
- Progression Free Survival （The time from the first day of treatment to the date on which disease progresses）(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19Non-hodgkin Lymphoma,B CellNCT03497533Timmune Biotech Inc.6
已完成
1 期
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's LymphomaB Cell Non-Hodgkin's LymphomaNCT05149391Peking University3
Unknown
1 期
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell MalignanciesB-cell MalignancyB-Cell Acute Lymphoblastic LeukaemiaB-cell LymphomaNCT03559439Shanghai Tong Ren Hospital9
招募中
1 期
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)NCT05474885iCell Gene Therapeutics15
Unknown
早期 1 期
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyNon-Hodgkin LymphomaNCT03790891Timmune Biotech Inc.12